You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. PLASMA & BIOTHERAPIES - 05-02-2015

    SIPPET Study: interim analysis confirms the original hypothesis

    The Study on inhibitors in Hemophilia A is safe to continue after Investigators’ Meeting in San Francisco (Dec 2014)

    read more 
  2. EVENTS - 12-01-2015

    Fighting diseases of the new-born: Kedrion attended UENPS conference

    The company also supported a mini-marathon to eradicate HDFN

    read more 
  3. CORPORATE - 26-11-2014

    Kedrion receives the “VedoGreen, Green Excellence in Innovation” Award

    The awards ceremony held in Milan on November 17, during Waiting for Expo 2015, Green Economy 2.0

    read more 

Pages

For more information please contact: pressoffice@kedrion.com